Literature DB >> 8544188

Absence of mutations in the promoter of the COL1A1 gene of type I collagen in patients with osteogenesis imperfecta type I.

M C Willing1, R L Slayton, S H Pitts, S P Deschenes.   

Abstract

Osteogenesis imperfecta type I results from decreased production of structurally normal type I collagen as a result of a COL1A1 "null" allele. Steady state amounts of COL1A1 mRNA are reduced in both the nucleus and cytoplasm of dermal fibroblasts from most affected subjects. Mutations involving key regulatory sequences in the COL1A1 promoter, such as the TATAAA and CCAAAT boxes, could alter steady state levels of mRNA, and therefore lead to this phenotype. To determine the frequency of such mutations in OI type I cell strains, we used PCR amplified genomic DNA in conjunction with denaturing gradient gel electrophoresis (DGGE) and SSCP, to screen the 5' untranslated domain, exon 1, and a small portion of intron 1 of the COL1A1 gene. In addition, direct sequence analysis was performed on an amplified genomic DNA fragment that included the TATAAA and CCAAAT boxes. Forty unrelated probands with OI type I, in whom no causative mutation was known, were included in the study. No mutations were included in the study. No mutations were identified in either the TATAAA or CCAAAT boxes in any of the affected people. In addition, there was little evidence of sequence diversity among any of the 40 subjects. These data suggest that mutations in the COL1A1 promoter do not play a significant role in the aetiology of OI type I.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8544188      PMCID: PMC1051669          DOI: 10.1136/jmg.32.9.697

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  34 in total

1.  Analysis of cytoplasmic and nuclear messenger RNA in fibroblasts from patients with type I osteogenesis imperfecta.

Authors:  C Genovese; D Rowe
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

2.  Detection of single base substitutions in total genomic DNA.

Authors:  R M Myers; N Lumelsky; L S Lerman; T Maniatis
Journal:  Nature       Date:  1985 Feb 7-13       Impact factor: 49.962

3.  Type I osteogenesis imperfecta: a nonfunctional allele for pro alpha 1 (I) chains of type I procollagen.

Authors:  G S Barsh; K E David; P H Byers
Journal:  Proc Natl Acad Sci U S A       Date:  1982-06       Impact factor: 11.205

4.  beta-Thalassemia in a Kurdish Jew. Single base changes in the T-A-T-A box.

Authors:  M Poncz; M Ballantine; D Solowiejczyk; I Barak; E Schwartz; S Surrey
Journal:  J Biol Chem       Date:  1982-06-10       Impact factor: 5.157

5.  Genetic heterogeneity in osteogenesis imperfecta.

Authors:  D O Sillence; A Senn; D M Danks
Journal:  J Med Genet       Date:  1979-04       Impact factor: 6.318

6.  Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes.

Authors:  M Kozak
Journal:  Cell       Date:  1986-01-31       Impact factor: 41.582

7.  A single-base substitution in the proximal Sp1 site of the human low density lipoprotein receptor promoter as a cause of heterozygous familial hypercholesterolemia.

Authors:  U M Koivisto; J J Palvimo; O A Jänne; K Kontula
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-25       Impact factor: 11.205

8.  Osteogenesis imperfecta type I: molecular heterogeneity for COL1A1 null alleles of type I collagen.

Authors:  M C Willing; S P Deschenes; D A Scott; P H Byers; R L Slayton; S H Pitts; H Arikat; E J Roberts
Journal:  Am J Hum Genet       Date:  1994-10       Impact factor: 11.025

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Diminished type I collagen synthesis and reduced alpha 1(I) collagen messenger RNA in cultured fibroblasts from patients with dominantly inherited (type I) osteogenesis imperfecta.

Authors:  D W Rowe; J R Shapiro; M Poirier; S Schlesinger
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.